Russell Investments Group Ltd. Raises Stock Holdings in CryoPort, Inc. $CYRX

Russell Investments Group Ltd. increased its position in CryoPort, Inc. (NASDAQ:CYRX) by 154.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,761 shares of the company’s stock after purchasing an additional 19,886 shares during the period. Russell Investments Group Ltd. owned 0.07% of CryoPort worth $199,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Millennium Management LLC grew its stake in CryoPort by 11.0% in the fourth quarter. Millennium Management LLC now owns 4,139,869 shares of the company’s stock worth $32,208,000 after purchasing an additional 409,353 shares during the period. Deutsche Bank AG grew its stake in CryoPort by 0.9% in the fourth quarter. Deutsche Bank AG now owns 1,397,121 shares of the company’s stock worth $10,870,000 after purchasing an additional 12,864 shares during the period. Dimensional Fund Advisors LP grew its stake in CryoPort by 8.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 850,216 shares of the company’s stock worth $6,615,000 after purchasing an additional 63,301 shares during the period. Silvercrest Asset Management Group LLC grew its stake in CryoPort by 77.0% in the fourth quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company’s stock worth $5,780,000 after purchasing an additional 323,216 shares during the period. Finally, Readystate Asset Management LP grew its stake in CryoPort by 91.6% in the first quarter. Readystate Asset Management LP now owns 500,344 shares of the company’s stock worth $3,042,000 after purchasing an additional 239,153 shares during the period. 92.90% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, CFO Robert Stefanovich sold 9,300 shares of CryoPort stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $8.67, for a total transaction of $80,631.00. Following the transaction, the chief financial officer directly owned 207,213 shares of the company’s stock, valued at $1,796,536.71. The trade was a 4.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ramkumar Mandalam sold 40,728 shares of CryoPort stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $7.24, for a total value of $294,870.72. Following the transaction, the director directly owned 92,328 shares in the company, valued at approximately $668,454.72. The trade was a 30.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 492,247 shares of company stock worth $3,384,579 over the last ninety days. 10.10% of the stock is owned by corporate insiders.

CryoPort Trading Down 0.6%

CryoPort stock opened at $8.81 on Wednesday. The business has a 50-day simple moving average of $7.91 and a two-hundred day simple moving average of $6.74. The company has a market cap of $441.12 million, a P/E ratio of 6.62 and a beta of 1.62. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $9.48. The company has a quick ratio of 15.47, a current ratio of 16.24 and a debt-to-equity ratio of 0.39.

CryoPort (NASDAQ:CYRX) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.09). The firm had revenue of $45.45 million for the quarter, compared to the consensus estimate of $41.74 million. CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. CryoPort has set its FY 2025 guidance at EPS. Analysts predict that CryoPort, Inc. will post -0.99 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on CYRX. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of CryoPort in a research report on Thursday, May 8th. KeyCorp raised CryoPort from a “sector weight” rating to an “overweight” rating and set a $15.00 price target for the company in a research report on Wednesday, August 6th. Stephens began coverage on CryoPort in a research report on Tuesday, July 22nd. They issued an “overweight” rating and a $13.00 price target for the company. Leerink Partnrs raised CryoPort from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, August 6th. Finally, Leerink Partners raised CryoPort from a “market perform” rating to an “outperform” rating and set a $16.00 price target for the company in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $12.00.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.